Abstract Number: 2229 • 2012 ACR/ARHP Annual Meeting
Analysis of Clinical, CRP- and MRI- Responses to TNF-Blockade in Axial Spondyloarthritis Patients with Short Vs Long Symptom Duration
Background/Purpose: To investigate the impact of disease duration on treatment response in patients with axial spondylarthritis (SPA) treated with etanercept (ETA) or adalimumab (ADA). Methods:…Abstract Number: 2220 • 2012 ACR/ARHP Annual Meeting
Development of the Pulsar (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry
Background/Purpose: The spondyloarthritides are a group of conditions characterized by inflammation in the axial skeleton or peripheral joints. The arthritis may present as the primary…Abstract Number: 539 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab for the Treatment of Peripheral Arthritis in Spondyloarthritis Patients without Ankylosing Spondylitis or Psoriatic Arthritis
Background/Purpose: The treatment of spondyloarthritis (SpA) has improved dramatically since the introduction of TNF-blockade. However, this therapy is only approved and reimbursed for the treatment…